Kendle Appoints Philip J.W. Davies Vice President, Phase I
Position to drive global business strategy required for successful delivery of early stage clinical trials.
Cincinnati, OH-January 14, 2008—Kendle (www.kendle.com), a leading, global full-service clinical research organization (CRO), today announced the appointment of Philip J.W. Davies to the position of vice president, Phase I. Davies will provide global leadership to strengthen and grow the company’s Phase I business which includes a clinical pharmacology unit in The Netherlands and a bioequivalence unit in West Virginia, and will focus on expanding Phase I capabilities globally. Davies will be based in Kendle’s Cincinnati headquarters and will report directly to Candace Kendle, chairman and chief executive officer.
“Phase I is a rapidly growing area of opportunity and is an integral part of Kendle’s business plan, with the market expected to grow between 13.4 and 16 percent annually through 2010,” said Kendle. “I am pleased to welcome Phil to this key leadership role as Kendle focuses on the strategic expansion of our early stage capabilities to meet our customers’ needs.”
Davies brings more than two decades of pharmacology expertise to this position. He joins Kendle from Eli Lilly and Company where he served most recently as director of global exploratory and program phase medical operations. He has been with Eli Lilly since 2001, serving in multiple roles of increasing responsibility, including director, global exploratory medicine operations; director, global clinical pharmacology operations; and director, U.S. clinical pharmacology operations. Prior to Eli Lilly, Davies served as director of Kendle’s clinical pharmacology unit in The Netherlands and previously held clinical pharmacology roles in Germany and the UK.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
